Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside By: Benzinga via Benzinga February 04, 2016 at 09:15 AM EST Seattle Genetics, Inc. (NASDAQ: SGEN) share are down 28 percent since January 4. Barclays’ Jonathan Eckard initiated ... Read More >> Related Stocks: Seagen Inc